Semaglutide vs Mazdutide

Semaglutide and Mazdutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

Semaglutide functions as a GLP-1 receptor agonist, which has been extensively studied for its role in regulating appetite and glucose metabolism. Approved by the FDA under the brand names Ozempic for type 2 diabetes and Wegovy for chronic weight management, Semaglutide has demonstrated significant efficacy in clinical trials. Research indicates that it can lead to substantial weight loss, improve glycemic control, and reduce cardiovascular risk factors in patients. For instance, the STEP trials, which included thousands of participants, reported an average weight loss of approximately 15% over 68 weeks for those receiving the treatment. However, the absence of a generic version and the potential for counterfeit products are critical considerations for researchers.

Mazdutide (IBI362) is a novel dual GLP-1 and glucagon receptor agonist, co-developed by Innovent Biologics and Eli Lilly, with a molecular weight of 4,563.06 g/mol. This peptide is designed to simultaneously activate GLP-1 receptors, promoting appetite suppression and glucose regulation, while also stimulating glucagon receptors to enhance energy expenditure and reduce hepatic fat. In June 2025, Mazdutide received approval from China's NMPA for chronic weight management, followed by approval for glycemic control in type 2 diabetes in September 2025. Clinical studies have shown that Mazdutide can lead to significant weight loss in obese Chinese adults and effectively control blood sugar levels, although further research is needed to establish its long-term effects and safety profile.

Both Semaglutide and Mazdutide are primarily investigated for their roles in weight management and metabolic health. Semaglutide has been additionally explored for cardiovascular benefits, as evidenced by its inclusion in studies assessing its impact on heart health among diabetic populations. In contrast, Mazdutide does not currently have additional unique research applications reported in the literature, focusing instead on its dual receptor agonist properties to address obesity and glycemic control. This distinction may influence researchers' decisions when selecting a peptide for specific therapeutic investigations.

Safety profiles for Semaglutide and Mazdutide reveal some common gastrointestinal side effects, typical of GLP-1 receptor agonists. Semaglutide is associated with transient events such as nausea, vomiting, diarrhea, and abdominal discomfort, which occur in more than 5% of trial participants. Serious adverse events, although rare, include pancreatitis and severe allergic reactions. Mazdutide shares similar gastrointestinal effects, with dose-dependent nausea and vomiting reported. Additionally, an increase in heart rate has been observed, aligning with effects seen in the GLP-1 agonist class. Understanding these safety considerations is essential for researchers when designing studies and interpreting results.